Tokyo, June 29 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061941) titled 'Real-World Characteristics, Treatment Patterns, and Outcomes of Patients with cEGFRm NSCLC Treated with amivantamab + lazertinib, osimertinib + chemotherapy, and osimertinib monotherapy in the 1L Setting (REDAdmiral): A Non-Interventional, Multi-Country, Multi-Center, Multi-Wave, Retrospective Chart Review Study' on June 29.
Study Type:
Observational
Primary Sponsor:
Institute - Janssen Pharmaceutical K.K.
Condition:
Condition - Non-small cell lung cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - collecting and analyzing data for adults with advanced/me...